Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ATX-898 in advanced solid tumors
2026-526514-85-00Phase 2Authorised
- Sponsor
- Antares Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of ATX-898 in Nonhematologic neoplasms and breast cancer (5 arms), sponsored by Antares Therapeutics. Primary endpoints: Safety and dose-limiting toxicities, Clinical safety assessments and 4 more. Planned start Oct 2026; status: authorised.
02
Drugs
ATX-898
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on 2026-526514-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526514-85-00.